Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

Cash to Debt 0.80
TNGN's Cash to Debt is ranked higher than
55% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. TNGN: 0.80 )
TNGN' s 10-Year Cash to Debt Range
Min: 0.67   Max: 3.07
Current: 0.8

F-Score: 2
Z-Score: -17.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

ROA (%) -73.58
TNGN's ROA (%) is ranked higher than
55% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. TNGN: -73.58 )
TNGN' s 10-Year ROA (%) Range
Min: -136.14   Max: -33.94
Current: -73.58

ROC (Joel Greenblatt) (%) -3655.73
TNGN's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. TNGN: -3655.73 )
TNGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3655.73   Max: -135.65
Current: -3655.73

EBITDA Growth (%) -48.70
TNGN's EBITDA Growth (%) is ranked higher than
53% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. TNGN: -48.70 )
TNGN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -48.7
Current: -48.7

EPS Growth (%) -47.30
TNGN's EPS Growth (%) is ranked higher than
54% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. TNGN: -47.30 )
TNGN' s 10-Year EPS Growth (%) Range
Min: 0   Max: -47.3
Current: -47.3

» TNGN's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TNGN Guru Trades in

TNGN Guru Trades in

TNGN Guru Trades in

Q2 2012

TNGN Guru Trades in Q2 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TNGN

No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )


EV-to-EBIT 19.60
TNGN's EV-to-EBIT is ranked higher than
56% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. TNGN: 19.60 )
TNGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 19.6

Valuation & Return

Forward Rate of Return (Yacktman) -35048.82
TNGN's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. TNGN: -35048.82 )
TNGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -35048.82

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Tengion, Inc., was incorporated in 2003 as a Delaware corporation. The Company is a regenerative medicine company engaged in discovering, developing, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Using its Organ Regeneration Platform, the Company creates these neo-organs using a patient's own cells, or autologous cells. Its proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. Its product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. In addition, its neo-organs are designed to replace the need to substitute other tissues of the body for a purpose to which they are poorly suited. Its Organ Regeneration Platform involves testing different combinations of cell types and biomaterials. The organ regeneration process enabled by its proprietary Organ Regeneration Platform involves the following steps: Isolation and expansion of progenitor cells; Seeding and growth; Implantation; and Regeneration. Its Neo-Urinary Conduit is a combination of autologous smooth muscle cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters, through a stoma, or hole in the abdomen, into a standard ostomy bag. It produces its Neo-Urinary Conduit using smooth muscle cells from a routine fat biopsy and not cells from the diseased bladder, eliminating the risk of reintroducing cancerous cells from the bladder into the patient. The company manufactures its product candidates in a facility specifically designed for the production of patient-specific materials and have implemented quality control systems to ensure its manufacturing processes and facilities comply with applicable current good manufacturing processes, or cGMP, current Good Tissue Practices, or cGTP, and medical device quality systems regulations, or QSR standards. Tengion and the Tengion logo are Company's registered trademarks and Tengion Neo-Urinary Conduit, Tengion Neo-Kidney, Tengion Neo-Kidney Augment, Tengion Neo-Vessel, Tengion Neo-Vessel Replacement, Tengion Neo-Bladder Replacement, Neo-Bladder Augment, Tengion Organ Regeneration Platform and Organ Regeneration Platform are its trademarks. It faces, intense competition from medical device, pharmaceutical, biopharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies that are generally engaged in tissue engineering and regenerative medicine activities or funding.
» More Articles for TNGN


Articles On GuruFocus.com
Tengion Inc. Reports Operating Results (10-Q) May 20 2010 

Personalized Checklist

Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial